Cargando…

Hepatitis C Virus Reactivation Following COVID-19 Vaccination – A Case Report

PURPOSE: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection impacted morbidity and mortality during the pandemic of 2020–2021. A number of anti-COVID-19 vaccines have been developed with an unprecedented speed. While these vaccines have good efficacy and are safe, the experience...

Descripción completa

Detalles Bibliográficos
Autores principales: Lensen, Ruud, Netea, Mihai G, Rosendaal, Frits R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8412816/
https://www.ncbi.nlm.nih.gov/pubmed/34512037
http://dx.doi.org/10.2147/IMCRJ.S328482
_version_ 1783747530708746240
author Lensen, Ruud
Netea, Mihai G
Rosendaal, Frits R
author_facet Lensen, Ruud
Netea, Mihai G
Rosendaal, Frits R
author_sort Lensen, Ruud
collection PubMed
description PURPOSE: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection impacted morbidity and mortality during the pandemic of 2020–2021. A number of anti-COVID-19 vaccines have been developed with an unprecedented speed. While these vaccines have good efficacy and are safe, the experience with their use is limited and hence the knowledge of rare side effects. Identifying rare complications is important for future safe use of these vaccines. MATERIALS AND METHODS: Here, we report a case of a 82-year old patient with dementia who was admitted to a nursing home in the Netherlands. After vaccination with COVID-19 vaccination, physical examinations and lab tests were performed. RESULTS: She had a reactivation of hepatitis C infection after vaccination with the mRNA-based Pfizer–BioNTech COVID-19 vaccine. This reactivation manifested with jaundice, loss of consciousness, hepatic coma and death. CONCLUSION: This reactivation of hepatitis C virus after vaccination with the Pfizer–BioNTech COVID‑19 vaccine suggests a need for critical consideration of individuals with prior HCV infection and considered for COVID-19 vaccination.
format Online
Article
Text
id pubmed-8412816
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-84128162021-09-09 Hepatitis C Virus Reactivation Following COVID-19 Vaccination – A Case Report Lensen, Ruud Netea, Mihai G Rosendaal, Frits R Int Med Case Rep J Case Report PURPOSE: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection impacted morbidity and mortality during the pandemic of 2020–2021. A number of anti-COVID-19 vaccines have been developed with an unprecedented speed. While these vaccines have good efficacy and are safe, the experience with their use is limited and hence the knowledge of rare side effects. Identifying rare complications is important for future safe use of these vaccines. MATERIALS AND METHODS: Here, we report a case of a 82-year old patient with dementia who was admitted to a nursing home in the Netherlands. After vaccination with COVID-19 vaccination, physical examinations and lab tests were performed. RESULTS: She had a reactivation of hepatitis C infection after vaccination with the mRNA-based Pfizer–BioNTech COVID-19 vaccine. This reactivation manifested with jaundice, loss of consciousness, hepatic coma and death. CONCLUSION: This reactivation of hepatitis C virus after vaccination with the Pfizer–BioNTech COVID‑19 vaccine suggests a need for critical consideration of individuals with prior HCV infection and considered for COVID-19 vaccination. Dove 2021-08-29 /pmc/articles/PMC8412816/ /pubmed/34512037 http://dx.doi.org/10.2147/IMCRJ.S328482 Text en © 2021 Lensen et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Case Report
Lensen, Ruud
Netea, Mihai G
Rosendaal, Frits R
Hepatitis C Virus Reactivation Following COVID-19 Vaccination – A Case Report
title Hepatitis C Virus Reactivation Following COVID-19 Vaccination – A Case Report
title_full Hepatitis C Virus Reactivation Following COVID-19 Vaccination – A Case Report
title_fullStr Hepatitis C Virus Reactivation Following COVID-19 Vaccination – A Case Report
title_full_unstemmed Hepatitis C Virus Reactivation Following COVID-19 Vaccination – A Case Report
title_short Hepatitis C Virus Reactivation Following COVID-19 Vaccination – A Case Report
title_sort hepatitis c virus reactivation following covid-19 vaccination – a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8412816/
https://www.ncbi.nlm.nih.gov/pubmed/34512037
http://dx.doi.org/10.2147/IMCRJ.S328482
work_keys_str_mv AT lensenruud hepatitiscvirusreactivationfollowingcovid19vaccinationacasereport
AT neteamihaig hepatitiscvirusreactivationfollowingcovid19vaccinationacasereport
AT rosendaalfritsr hepatitiscvirusreactivationfollowingcovid19vaccinationacasereport